Sammler E, Juettler E, Geletneky K, Steiner T
Neurologische Klinik, Universität Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg.
Nervenarzt. 2006 Sep;77 Suppl 1:S39-48; quiz S49-50. doi: 10.1007/s00115-006-2139-2.
Spontaneous intracerebral haemorrhage (ICH) is a common and serious disease. It is responsible for 10-17% of all strokes, and mortality exceeds 50%. A variety of underlying causes exist for ICH, advancing age and hypertension being the most important risk factors. Other causes of ICH include vascular malformations, coagulation disorders, and use of anticoagulants and thrombolytic agents. Treatment options comprise conservative as well as surgical management. In addition, a recently published clinical trial evaluating the use of activated recombinant Factor VII allows specific haemostatic therapies to be used in ICH treatment. That and other studies have significantly added to the understanding of the disease. The European Stroke Initiative, which represents the European Stroke Council, European Neurological Society, and European Federation of Neurological Societies, will soon publish recommendations for the management of spontaneous intracerebral haemorrhages. Those recommendations form the basis of this article.
自发性脑出血（ICH）是一种常见且严重的疾病。它占所有中风病例的10 - 17%，死亡率超过50%。ICH存在多种潜在病因，年龄增长和高血压是最重要的风险因素。ICH的其他病因包括血管畸形、凝血障碍以及使用抗凝剂和溶栓剂。治疗选择包括保守治疗和手术治疗。此外，最近一项评估重组活化因子VII使用情况的临床试验使得特定的止血疗法可用于ICH治疗。该项研究及其他研究极大地增进了我们对该疾病的了解。代表欧洲中风理事会、欧洲神经学会和欧洲神经学会联合会的欧洲中风倡议组织即将发布关于自发性脑出血管理的建议。这些建议构成了本文的基础。
